173 related articles for article (PubMed ID: 2775304)
1. The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man.
Kobayashi S; Murray S; Watson D; Sesardic D; Davies DS; Boobis AR
Biochem Pharmacol; 1989 Sep; 38(17):2795-9. PubMed ID: 2775304
[TBL] [Abstract][Full Text] [Related]
2. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS
Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021
[TBL] [Abstract][Full Text] [Related]
3. 4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine.
Granvil CP; Krausz KW; Gelboin HV; Idle JR; Gonzalez FJ
J Pharmacol Exp Ther; 2002 Jun; 301(3):1025-32. PubMed ID: 12023534
[TBL] [Abstract][Full Text] [Related]
4. Quinine is a more potent inhibitor than quinidine in rat of the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase.
Muralidharan G; Hawes EM; McKay G; Midha KK
Xenobiotica; 1991 Nov; 21(11):1441-50. PubMed ID: 1763518
[TBL] [Abstract][Full Text] [Related]
5. Quinidine but not quinine inhibits in man the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase.
Muralidharan G; Hawes EM; McKay G; Korchinski ED; Midha KK
Eur J Clin Pharmacol; 1991; 41(5):471-4. PubMed ID: 1761076
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of quinidine and quinine on liver microsome oxidation enzymes in man and rat.
Tu ZG; Zhao LL
Zhongguo Yao Li Xue Bao; 1996 Nov; 17(6):541-4. PubMed ID: 9863152
[TBL] [Abstract][Full Text] [Related]
7. In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver.
Otton SV; Brinn RU; Gram LF
Drug Metab Dispos; 1988; 16(1):15-7. PubMed ID: 2894945
[TBL] [Abstract][Full Text] [Related]
8. Bufuralol 1'-hydroxylase activity of the rat. Strain differences and the effects of inhibitors.
Boobis AR; Seddon CE; Davies DS
Biochem Pharmacol; 1986 Sep; 35(17):2961-5. PubMed ID: 3741485
[TBL] [Abstract][Full Text] [Related]
9. Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man.
Boobis AR; Murray S; Kahn GC; Robertz GM; Davies DS
Mol Pharmacol; 1983 Mar; 23(2):474-81. PubMed ID: 6220203
[TBL] [Abstract][Full Text] [Related]
10. Catalytic activities of human debrisoquine 4-hydroxylase cytochrome P450 (CYP2D6) expressed in yeast.
Ellis SW; Ching MS; Watson PF; Henderson CJ; Simula AP; Lennard MS; Tucker GT; Woods HF
Biochem Pharmacol; 1992 Aug; 44(4):617-20. PubMed ID: 1510710
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of cytochrome P450 isoform activities in the female dark agouti (DA) rat: relevance to its use as a model of the CYP2D6 poor metaboliser phenotype.
Barham HM; Lennard MS; Tucker GT
Biochem Pharmacol; 1994 Apr; 47(8):1295-307. PubMed ID: 8185638
[TBL] [Abstract][Full Text] [Related]
12. Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes.
Bertilsson L; Meese CO; Yue QY; Dahl ML; Ingelman-Sundberg M; Johansson I; Säwe J; Eichelbaum M
Pharmacogenetics; 1993 Apr; 3(2):94-100. PubMed ID: 8100167
[TBL] [Abstract][Full Text] [Related]
13. Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase).
Tyndale RF; Kalow W; Inaba T
Br J Clin Pharmacol; 1991 Jun; 31(6):655-60. PubMed ID: 1867960
[TBL] [Abstract][Full Text] [Related]
14. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes.
Otton SV; Crewe HK; Lennard MS; Tucker GT; Woods HF
J Pharmacol Exp Ther; 1988 Oct; 247(1):242-7. PubMed ID: 3171974
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of imipramine metabolism by human liver microsomes.
Skjelbo E; Brøsen K
Br J Clin Pharmacol; 1992 Sep; 34(3):256-61. PubMed ID: 1389950
[TBL] [Abstract][Full Text] [Related]
16. Impairment of debrisoquine 4-hydroxylase and related monooxygenase activities in the rat following treatment with propranolol.
Masubuchi Y; Fujita S; Chiba M; Kagimoto N; Umeda S; Suzuki T
Biochem Pharmacol; 1991 Mar 15-Apr 1; 41(6-7):861-5. PubMed ID: 2009081
[TBL] [Abstract][Full Text] [Related]
17. Evidence that serine 304 is not a key ligand-binding residue in the active site of cytochrome P450 2D6.
Ellis SW; Hayhurst GP; Lightfoot T; Smith G; Harlow J; Rowland-Yeo K; Larsson C; Mahling J; Lim CK; Wolf CR; Blackburn MG; Lennard MS; Tucker GT
Biochem J; 2000 Feb; 345 Pt 3(Pt 3):565-71. PubMed ID: 10642515
[TBL] [Abstract][Full Text] [Related]
18. Potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine, quinidine, and its metabolites.
Ching MS; Blake CL; Ghabrial H; Ellis SW; Lennard MS; Tucker GT; Smallwood RA
Biochem Pharmacol; 1995 Sep; 50(6):833-7. PubMed ID: 7575645
[TBL] [Abstract][Full Text] [Related]
19. Mutual inhibition between quinine and etoposide by human liver microsomes. Evidence for cytochrome P4503A4 involvement in their major metabolic pathways.
Zhao XJ; Kawashiro T; Ishizaki T
Drug Metab Dispos; 1998 Feb; 26(2):188-91. PubMed ID: 9456308
[TBL] [Abstract][Full Text] [Related]
20. Assay and characterisation of debrisoquine 4-hydroxylase activity of microsomal fractions of human liver.
Kahn GC; Boobis AR; Murray S; Brodie MJ; Davies DS
Br J Clin Pharmacol; 1982 May; 13(5):637-45. PubMed ID: 7082530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]